Letrozolo Zentiva (Letrozole)

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens to estrogen. This lowers circulating estrogen levels, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby inhibiting tumor proliferation.

The prescribed dose of Letrozolo Zentiva is determined by the treating physician based on the patient’s clinical condition, treatment setting and individual response. Typically, the medication is taken once daily, but exact dosing must follow the prescriber’s instructions.

Letrozole is contraindicated in pregnancy because it can harm the developing fetus. Women of childbearing potential should use effective contraception during treatment. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on letrozole.

To request Letrozolo Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Letrozolo Zentiva (letrozole) is a third‑generation aromatase inhibitor with a long half‑life, allowing once‑daily dosing. Compared with anastrozole or exemestane, letrozole often provides slightly greater estrogen suppression, which may translate into marginally higher efficacy in certain settings, though safety profiles are broadly similar.

Store Letrozolo Zentiva tablets at ambient temperature, preferably below 25 °C, in the original blister pack. Protect from moisture, heat and direct sunlight. Keep the product out of reach of children and do not use after the expiry date.

Letrozolo Zentiva is taken orally as a tablet. Swallow the tablet whole with a glass of water, preferably at the same time each day. It may be taken with or without food, but consistency helps maintain stable drug levels.

Serious risks include significant bone loss leading to osteoporosis or fractures, severe liver injury, and rare thromboembolic events such as pulmonary embolism. Patients should be monitored regularly for bone density, liver function and signs of clotting disorders.

Letrozolo Zentiva should not be used in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any tablet excipients. Caution is also advised for patients with severe liver impairment or uncontrolled cardiovascular disease.